Figure 4.

Sagittal view of fused whole-body and brain-focused µSPECT/CT scan images of anti-HER2 [¹¹¹In]-2Rs15d, non-targeting [¹¹¹In]-R3B23 and anti-HER2 [¹¹¹In]-trastuzumab 1 h and 3 days p.i. in SKOV3.IP1 (Left) and 231Br (Right) tumor models. One representative image of each group (n = 4) is shown. Tumor-targeting is visible for [¹¹¹In]-2Rs15d in both tumor models, whereas [¹¹¹In]-trastuzumab was only able to accumulate in 231Br tumors. High uptake was also observed in highly vascularized organs up to 3 days after injection. There was no aspecific leakage of non-targeting [¹¹¹In]-R3B23 into the tumor site. T: tumor, Bl: blood, K: kidney, H: heart, L: liver, B: bladder, TB: total body, BF: brain focus.